Business
ENDRA Life Sciences Announces New Clinical Study Partnership with the Medical College of Wisconsin (MCW)
Study to Bolster Clinical Evidence of Performance of Patented TAEUS Ultrasound Device in NAFLD Patients as Commercialization Begins ANN ARBOR, MI / ACCESSWIRE
About this update from Endra Life Sciences Inc.
[{"type":"text","content":"Study to Bolster Clinical Evidence of Performance of Patented TAEUS Ultrasound Device in NAFLD Patients as Commercialization Begins ANN ARBOR, MI / ACCESSWIRE / June 8, 2020 / ENDRA Life Sciences Inc. (\"ENDRA\") (NASDAQ:NDRA), a pioneer of enhanced ultrasound technologies, today announced that the Medical College of Wisconsin (\"MCW\") a world-renowned healthcare institution, is partnering with ENDRA for a clinical study of ENDRA's Thermo-Acoustic Enhanced Ultrasound (TAEUS™) device for assessing Non-Alcoholic Fatty Liver Disease (\"NAFLD\").\"We are thrilled that MCW, a renowned research institution and pioneer in liver disease management and transplantation is evaluating TAEUS as a tool to characterize NAFLD, a condition that impacts more than one billion people globally,\" said ENDRA Life Sciences CEO, Francois Michelon. \"It's an honor for ENDRA to garner the clinical interest of another leading research institution. We look forward to building our relationship with MCW as we commercialize TAEUS starting in the second half of this year.\"This represents the third clinical research partnership for ENDRA in the United States and is a natural progression from the feasibility study conducted by the Robarts Research Institute, which used healthy volunteers to establish the safety and efficacy of the TAEUS technology. The data from the MCW study, along with other ongoing or to-be initiated studies, will be used to bolster the clinical evidence and further establish the clinical utility of the TAEUS ultrasound device in patients with NAFLD, as commercialization begins in the second half of the year. The study will be led by Dr. Achuthan Sourianarayanane, MD, MRCP, Assistant Professor at MCW in the Gastroenterology and Hepatology department, practicing at Froedtert Hospital.\"Currently, the options to assess and monitor liver fat in NAFLD patients, namely MRI and liver biopsy, are difficult to integrate into clinical practice. There is a great need for more practical tools to help manage patients with this chronic condition,\" said Dr. Sourianarayanane. \"We are excited to conduct this study of TAEUS in our patients with NAFLD, and to better understand the potential clinical utility of ENDRA's TAEUS technology.\"The goals of the MCW study, include:Comparing ENDRA's commercial design TAEUS liver device against a baseline measure of ...